3 results about "Clear cell carcinoma" patented technology

The application provides a polymer carbon nitride@Hittorf red phosphorus heterostructure and application thereof in preparation of a medicine for targeted treatment of renal clear cell carcinoma, and belongs to the technical field of nano medicines. The application designs a near-infrared light response Hittorf red phosphorus (HP) modified polymer carbon nitride heterostructure (PCN@HP) based on a simple chemical vapor deposition (CVD) method. Experimental research finds that the HP nanorods vertically grown on the PCN exhibit wide and strong light absorption in the near-infrared range. In-vivo and in-vitro experiments prove that under near-infrared light irradiation, when the concentration of the suspension is 100 μg / mL, the tumor inhibition rate reaches 100%. Notably, the composite has no damage to normal tissues and cells, but it has obvious targeted inhibition effect on deep ccRCC cells in the body. In addition, the composite material has good biocompatibility and spontaneous light effect, and can be completely metabolized in the body within 48 hours, and is a kind of nanoparticle with imaging and PDT / PTT synergistic treatment, and can be used for efficient tumor nano treatment.

Provided herein are methods and compositions for reducing the expression and / or activity of an oncogenic transfer RNA (tRNA). Composition for treating cancer in the subject are disclosed, comprising an inhibitor of an oncogenic transfer RNA (tRNA) to a subject in need thereof, wherein the oncogenic tRNA comprises an inhibitory nucleic acid such as ARG-TCT-4-1, an siRNA, an shRNA, an miRNA, an antisense oligonucleotide, or a nucleic acid modification such as a locked nucleic acid, a phosphorothioate modification, a 2′—O-methyl modification, a 2′—O-methoxyethyl modification, a 2′-fluoro modification, a phosphorodiamidate modification, or a mesylphosphoramidate modification. The disclosed compositions are disclosed as treating cancers such as a sarcoma, a glioblastoma, an adrenocortical carcinoma, a cholangiocarcinonma, a melanoma, a glioma, a diffuse glioma, a mature B cell neoplasm, a non-small cell lung cancer, an esophagogastric adenocarcinoma, a pheochromocytoma, a hepatocellular carcinoma, an endometrial carcinoma, a pancreatic adenocarcinoma, a breast carcinoma, an invasive breast carcinoma, a head and neck squamous cell carcinoma, a bladder urothelial carcinoma, a colorectal adenocarcinoma, an ovarian epithelial tumor, a prostate adenocarcinoma, a cervical squamous cell carcinoma, a renal non-clear cell carcinoma, or a renal clear cell carcinoma.

The application provides a use of an NR2F2 agonist levomilnacipran in preparation of a drug for treating female renal clear cell carcinoma (ccRCC). In an estrogen environment, the levomilnacipran can significantly promote expression of NR2F2, and significantly inhibit proliferation, invasion and migration of ccRCC cells. The levomilnacipran can be used as a novel therapeutic drug for female ccRCC, and can specifically inhibit progression of the female ccRCC, and has important significance for disease prognosis.